Efavirenz to Nevirapine Switch in HIV-Infected Patients with Dyslipidemia
Efavirenz to Nevirapine Switch in HIV-Infected Patients with Dyslipidemia
Francisco Blanco
NULL
*Correspondence: Francisco Blanco, Email not available
Abstract
Many antiretroviral therapies, including efavirenz,are associated with increased serum concentrations of LDL-cholesterol. In a 52-week randomized study,French researchers (Parienti, et al. Clin Infect Dis2007;45:263-6) found that switching from efavirenzto nevirapine was associated with a significant decreasein LDL-cholesterol levels, compared withcontinuation of efavirenz therapy.
